Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 56 and Dextrose 5% is a crystalloid solution that provides electrolytes and carbohydrates. Dextrose is metabolized to glucose, which is utilized for cellular energy production. The electrolytes (sodium, chloride, potassium, magnesium, and acetate) maintain or restore intravascular volume, acid-base balance, and osmotic gradients. Acetate is metabolized to bicarbonate, providing an alkalinizing effect.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Intravenous infusion for fluid and electrolyte replacement in patients with mild to moderate fluid loss,Source of calories (dextrose) and electrolytes,Maintenance of hydration and electrolyte balance,Treatment of metabolic acidosis (alkalinizing effect from acetate),Off-label: Use as a vehicle for drug administration
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; dose depends on fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, rate up to 333 m L/hour. Maximum 3 L/24 hours.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable; composition-dependent. Dextrose half-life ~2 hours. Electrolytes follow endogenous regulation; no terminal elimination half-life defined.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Dextrose is metabolized via glycolysis and the Krebs cycle. Acetate is metabolized in the liver and peripheral tissues to bicarbonate. Electrolytes are not metabolized.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal 100% (electrolytes and dextrose metabolized to CO2 and water; excess water and electrolytes excreted unchanged in urine).
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
<5% (minimal; free ions and glucose).
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
0.2-0.3 L/kg (dextrose and electrolytes distribute primarily in extracellular fluid; total body water for water).
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100%.
100% intravenous; not administered by other routes.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload. For GFR 30-60 m L/min: monitor potassium and fluid status closely; reduce infusion rate and volume.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
Use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid overload and electrolyte imbalances. No specific dose adjustment defined; monitor closely.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Weight-based: 20-40 m L/kg per dose as a single infusion, rate not to exceed 10 m L/kg/hour. For maintenance: 100-150 m L/kg/day, adjusted for age and clinical status.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution due to decreased renal function; consider baseline GFR. Reduce rate and total volume to avoid fluid overload. Monitor electrolytes and volume status frequently.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None
Not applicable; no FDA boxed warning exists for this product.
Use with caution in patients with renal impairment, heart failure, or conditions with fluid overload,Risk of electrolyte disturbances (hyperkalemia, hypermagnesemia, hypernatremia) with excessive or rapid infusion,May cause hyperglycemia in patients with diabetes mellitus or glucose intolerance,Avoid in patients with severe metabolic acidosis without adequate buffering capacity,Monitor serum electrolytes, glucose, fluid balance, and acid-base status during prolonged therapy,Not recommended for use in neonates or pediatric patients with significant renal impairment due to potassium content
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hyperkalemia,Hypernatremia,Severe renal failure with oliguria or anuria,Severe metabolic acidosis (e.g., lactic acidosis, diabetic ketoacidosis),Concurrent administration of medications that may exacerbate hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors),Patients with known allergy to any component
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No dietary restrictions are required. However, this solution contains dextrose, which may affect blood glucose; diabetic patients should monitor carbohydrate intake accordingly. No known food interactions.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
First trimester: No known teratogenic effects. Dextrose and electrolytes are physiological components; no structural anomalies reported. Second and third trimesters: No fetal risk; used for fluid and electrolyte maintenance. High dextrose concentrations may cause maternal hyperglycemia, potentially leading to fetal hyperinsulinemia and neonatal hypoglycemia if infused rapidly or in large volumes.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Dextrose and electrolytes are normal constituents of breast milk. No adverse effects expected. M/P ratio not applicable as components are endogenous.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No dose adjustment needed for pregnancy-specific pharmacokinetic changes. However, the increased blood volume and glomerular filtration rate may necessitate faster infusion rates to maintain adequate volume; caution to avoid fluid overload. Dextrose infusion rate should be adjusted to maintain maternal blood glucose < 130 mg/d L to prevent fetal hyperinsulinemia.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
PLASMA-LYTE 56 AND DEXTROSE 5% is an isotonic solution containing electrolytes and a low dextrose concentration (5 g/d L). It provides 170 m Osm/L, making it hypotonic relative to plasma. Use cautiously in patients with increased risk of hyponatremia or cerebral edema (e.g., children, elderly, post-op). Co-administration of dextrose may cause hyperglycemia; monitor blood glucose in diabetics. Not for use as a sole source of calories; dextrose concentration insufficient for nutritional support. Contraindicated in patients with hyperkalemia, hypercalcemia, or severe lactic acidosis. Do not administer if solution is discolored or contains particulates.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This intravenous solution provides fluids, sugar, and electrolytes to maintain hydration and balance.,Tell your healthcare provider if you have diabetes, kidney disease, heart failure, or electrolyte disorders.,Report any symptoms like headache, nausea, confusion, or swelling during infusion.,This solution is given through a vein; do not adjust the flow rate yourself.,If you experience pain, redness, or swelling at the infusion site, notify your nurse immediately.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 56 and Dextrose 5% is a crystalloid solution that provides electrolytes and carbohydrates. Dextrose is metabolized to glucose, which is utilized for cellular energy production. The electrolytes (sodium, chloride, potassium, magnesium, and acetate) maintain or restore intravascular volume, acid-base balance, and osmotic gradients. Acetate is metabolized to bicarbonate, providing an alkalinizing effect.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, rate up to 333 m L/hour. Maximum 3 L/24 hours.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. First trimester: No known teratogenic effects. Dextrose and electrolytes are physiological components; no structural anomalies reported. Second and third trimesters: No fetal risk;. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.